Regulatory Q&A Forum
Ask questions, share knowledge, and get help from the regulatory community
When budgeting for long-term compliance into 2026, what key factors and service-level differences should a medical device or Software as a Medical Device (SaMD) manufacturer evaluate to accurately for...
When non-EU manufacturers evaluate the costs associated with appointing an authorized representative for the Carbon Border Adjustment Mechanism (CBAM), it is crucial to first distinguish this role fro...
With the implementation of the Modernization of Cosmetics Regulation Act (MoCRA), foreign cosmetic facilities face new mandatory requirements for U.S. market access, including the designation of a Uni...
With significant EU regulatory updates for cosmetics, including new substance restrictions, anticipated to take effect by 2026, how should a non-EU brand evolve its due diligence process for selecting...
When developing a premarket submission for a medical device with significant software or connectivity features, such as a Software as a Medical Device (SaMD) or a wearable cardiac monitor, how can spo...
For non-EU manufacturers, selecting an EU Authorized Representative (AR) under the Medical Device Regulation (MDR - Regulation EU 2017/745) is a critical compliance step that extends far beyond a simp...
Given the dynamic nature of U.S. medical device regulations, including significant anticipated updates like the Quality Management System Regulation (QMSR), how should foreign establishments re-evalua...
When selecting an external Person Responsible for Regulatory Compliance (PRRC) service for 2026 and beyond, how can medical device manufacturers move beyond basic credential checks to perform truly ro...
For a non-EU manufacturer of a connected medical device, such as a diagnostic SaMD that processes patient data, what is a robust framework for selecting a GDPR Article 27 Representative in preparation...
While manufacturers frequently ask for a simple price for an EU Authorized Representative (AR), a more useful question is: what key factors determine the cost and scope of EU AR services under the Med...
With the FDA's transition from the existing Quality System Regulation (QSR) to the new Quality Management System Regulation (QMSR) taking effect in 2026, how should a foreign medical device manufactur...
How can medical device manufacturers, particularly small to medium-sized enterprises, develop a robust evaluation framework for selecting a "Person Responsible for Regulatory Compliance" (PRRC) as a S...
Given that the ECHA Forum’s 2026 inspection project will specifically target the compliance of Only Representatives (ORs), how can a non-EU manufacturer move beyond a simple cost comparison and conduc...
Given the significantly expanded legal responsibilities and shared liability for defective devices assigned to the EU Authorized Representative (AR) under Article 11 of the Medical Device Regulation (...
When a foreign cosmetic facility seeks to appoint an FDA U.S. Agent to comply with new requirements under the Modernization of Cosmetics Regulation Act (MoCRA), what are the key factors and service-le...
For medical device manufacturers, especially small or micro-enterprises, selecting a "Person Responsible for Regulatory Compliance (PRRC) as a Service" provider is a critical decision for meeting EU M...
With the European Chemicals Agency (ECHA) announcing a pilot inspection project for Only Representatives (ORs) planned for 2026, how should non-EU manufacturers proactively assess their current or pot...
For a manufacturer of a connected Class II medical device, such as a Software as a Medical Device (SaMD) or a wearable cardiac monitor, how should the principles from FDA’s guidance on cybersecurity b...
When foreign cosmetic facilities evaluate the cost of appointing a U.S. Agent as required by the Modernization of Cosmetics Regulation Act (MoCRA), what key factors and service-level differences shoul...
How can a medical device manufacturer effectively evaluate a "Person Responsible for Regulatory Compliance (PRRC) as a Service" provider to ensure they are not only qualified under EU MDR Article 15 b...